These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24347426)

  • 1. Effects of raloxifene and estrogen on bioactive IGF1 in GH-deficient women.
    Birzniece V; Magnusson NE; Ho KK; Frystyk J
    Eur J Endocrinol; 2014 Mar; 170(3):375-83. PubMed ID: 24347426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women.
    Birzniece V; Meinhardt U; Gibney J; Johannsson G; Baxter RC; Seibel MJ; Ho KK
    J Clin Endocrinol Metab; 2010 May; 95(5):2099-106. PubMed ID: 20207825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women.
    Gibney J; Johannsson G; Leung KC; Ho KK
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3897-903. PubMed ID: 15855258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.
    Birzniece V; Meinhardt UJ; Gibney J; Johannsson G; Armstrong N; Baxter RC; Ho KK
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1005-12. PubMed ID: 22170716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study.
    Isotton AL; Wender MC; Casagrande A; Rollin G; Czepielewski MA
    Eur J Endocrinol; 2012 Feb; 166(2):207-13. PubMed ID: 22108915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism.
    van der Klaauw AA; Biermasz NR; Zelissen PM; Pereira AM; Lentjes EG; Smit JW; van Thiel SW; Romijn JA; Roelfsema F
    Eur J Endocrinol; 2007 Dec; 157(6):709-16. PubMed ID: 18057377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency.
    Janssen YJ; Helmerhorst F; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 2000 Jan; 85(1):464-7. PubMed ID: 10634425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
    Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.
    Birzniece V; Sutanto S; Ho KK
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E521-7. PubMed ID: 22319035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and total IGFBP3 for the assessment of disorders of the GH/IGF1 axis in children with chronic kidney disease, GH deficiency, or short stature after SGA status at birth.
    Büscher AK; Büscher R; Pridzun L; Langkamp M; Wachendorfer N; Hoyer PF; Ranke MB; Hauffa BP
    Eur J Endocrinol; 2012 May; 166(5):923-31. PubMed ID: 22318747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of IGF1 estimation in adults with GH deficiency.
    Mukherjee A; Shalet SM
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S33-9. PubMed ID: 19684059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized GH trial with two different dosages in combination with a GnRH analogue in short small for gestational age children: effects on metabolic profile and serum GH, IGF1, and IGFBP3 levels.
    van der Kaay D; Bakker B; van der Hulst F; Mul D; Mulder J; Schroor E; van Elswijk D; Rowaan I; Willeboer M; de Ridder M; Hokken-Koelega A
    Eur J Endocrinol; 2010 May; 162(5):887-95. PubMed ID: 20176737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
    Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
    Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency.
    Peter F; Savoy C; Ji HJ; Juhasz M; Bidlingmaier M; Saenger P
    Eur J Endocrinol; 2009 Mar; 160(3):349-55. PubMed ID: 19074465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak.
    Feldt-Rasmussen U; Brabant G; Maiter D; Jonsson B; Toogood A; Koltowska-Haggstrom M; Rasmussen AK; Buchfelder M; Saller B; Biller BM
    Eur J Endocrinol; 2013 May; 168(5):733-43. PubMed ID: 23416951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women.
    Wolthers T; Hoffman DM; Nugent AG; Duncan MW; Umpleby M; Ho KK
    Am J Physiol Endocrinol Metab; 2001 Dec; 281(6):E1191-6. PubMed ID: 11701433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is growth without IGF1 possible? A case report.
    Flader M; Zalas D; Niedziela M
    Pediatr Endocrinol Diabetes Metab; 2017; 23(4):215-220. PubMed ID: 29574475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary-independent effect of octreotide on IGF1 generation.
    Pokrajac A; Frystyk J; Flyvbjerg A; Trainer PJ
    Eur J Endocrinol; 2009 Apr; 160(4):543-8. PubMed ID: 19141605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.